Boehringer Ingelheim to advance Survodutide into 3 global Phase III studies in obesity Ruchika Sharma20 Aug 2023 10:00 AM ISTGermany: Boehringer Ingelheim has announced it will advance survodutide, its glucagon/GLP-1 receptor dual agonist, into three registrational Phase III...
Lupin buys diabetes brands Ondero, Ondero Met from Boehringer Ingelheim International for Rs 235 Crore Ruchika Sharma19 Aug 2023 2:27 PM ISTMumbai: Global pharma major Lupin Limited has announced the acquisition of diabetes brands ONDERO and ONDERO MET, from Boehringer Ingelheim...
USFDA accepts application for Boehringer Ingelheim OFEV for children, adolescents aged 6-17 years old with fibrosing interstitial lung disease Ruchika Sharma27 July 2023 1:30 PM ISTRidgefield: Boehringer Ingelheim has announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application...
Eli Lilly- Boehringer Ingelheim Jardiance gets European Commission nod to treat adults with CKD Ruchika Sharma26 July 2023 4:30 PM ISTIngelheim: The European Commission (EC) has approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD),...
First trial over heartburn drug Zantac cancer claims expected in November Ruchika Sharma3 July 2023 2:30 PM ISTNew York: The first U.S. trial over claims that discontinued heartburn drug Zantac causes cancer is now expected to take place in California state...
AstraZeneca former Chief Gagandeep Singh joins Boehringer Ingelheim as MD, Head of Human Pharma India Ruchika Sharma26 Jun 2023 5:12 PM ISTGagandeep Singh joins Boehringer Ingelheim from AstraZeneca, where he was the Managing Director for India and Africa Cluster Head.
Eli Lilly-Boehringer Ingelheim bags USFDA nod for Type 2 diabetes drugs Jardiance, Synjardy for children Ruchika Sharma21 Jun 2023 4:30 PM ISTUnited States: The U.S. Food and Drug Administration (FDA) on Tuesday approved Eli Lilly and partner Boehringer Ingelheim's drugs Jardiance and...
Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim Ruchika Sharma21 Jun 2023 1:30 PM ISTThere is no evidence of consumer harm from real world use of Zantac as a result of any NDMA contamination.
Boehringer Ingelheim starts clinical development of fibrotic diseases treatment Ruchika Sharma10 May 2023 4:30 PM ISTIL-11 plays a key role in fibrosis across multiple organs and pre-clinical studies have shown that anti-IL-11 treatment has the potential to stop -...
Boehringer Ingelheim Spesolimab bags USFDA Breakthrough Therapy Designation for prevention of generalized pustular psoriasis flares Ruchika Sharma3 May 2023 2:30 PM ISTGeneralized pustular psoriasis is a rare and potentially life-threatening chronic neutrophilic skin disease characterized by flares of widespread...
Boehringer Ingelheim, Cognizant ink pact on Unified Cloud Platform to speed delivery of life saving therapies Ruchika Sharma13 April 2023 11:15 AM ISTBy bringing together Boehringer Ingelheim's clinical, regulatory, and quality functions onto this unified platform simultaneously, this holistic...
Boehringer Ingelheim gets CDSCO panel nod to market Spesolimab indicated for generalized pustular psoriasis Dr. Divya Colin11 March 2023 6:00 PM ISTNew Delhi: Granting the local clinical trial waiver, the Subject Expert Committee (SEC) functional under the Central Drug Standard Control...
